La radiothérapie du cancer de la prostate augmente-t-elle le risque de seconds cancers ?

• Published in: Cancer radiothérapie
• Main Authors: Boué-Raflé, A., Briens, A, Supiot, S., Blanchard, P., Baty, M, Lafond, C., Masson, I., Créhange, G., Cosset, J.M., Pasquier, D., de Crevoisier, R
• Format: Journal Article
• Language: French
• Published: Elsevier Masson 2024
• Subjects: Bioengineering; Life Sciences; Radio-induced; Radiothérapie; Second cancer; Radio-induit; Radiotherapy; Second primary cancer; Prostate cancer; Prostate; Cancer
• ISSN: 1278-3218; 1769-6658
• DOI: 10.1016/j.canrad.2023.07.018

Purpose: The increased risk of second cancer after prostate radiotherapy is a debated clinical concern. The objective of the study was to assess the risk of occurrence of second cancers after prostate radiation therapy based on the analysis the literature, and to identify potential factors explaining the discrepancies in results between studies.Materials and methods: A review of the literature was carried out, comparing the occurrence of second cancers in patients all presenting with prostate cancer, treated or not by radiation.Results: This review included 30 studies reporting the occurrence of second cancers in 2,112,000 patients treated or monitored for localized prostate cancer, including 1,111,000 by external radiation therapy and 103,000 by brachytherapy. Regarding external radiation therapy, the average follow-up was 7.3years. The majority of studies (80%) involving external radiation therapy, compared to no external radiation therapy, showed an increased risk of second cancers with a hazard ratio ranging from 1.13 to 4.9, depending on the duration of the follow-up. The median time to the occurrence of these second cancers after external radiotherapy ranged from 4 to 6years. An increased risk of second rectal and bladder cancer was observed in 52% and 85% of the studies, respectively. Considering a censoring period of more than 10 years after irradiation, 57% and 100% of the studies found an increased risk of rectal and bladder cancer, without any impact in overall survival. Studies of brachytherapy did not show an increased risk of second cancer. However, these comparative studies, most often old and retrospective, had many methodological biases.Conclusion: Despite numerous methodological biases, prostate external radiation therapy appears associated with a moderate increase in the risk of second pelvic cancer, in particular bladder cancer, without impacting survival. Brachytherapy does not increase the risk of a second cancer.